Get the Stockscreener App
1.585
0.32%
-0.005
Inovio Pharmaceuticals Inc stock is traded at $1.585, with a volume of 260.72K.
It is down -0.32% in the last 24 hours and down -12.98% over the past month.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
See More
Previous Close:
$1.58
Open:
$1.59
24h Volume:
260.72K
Relative Volume:
0.20
Market Cap:
$109.01M
Revenue:
$65,300
Net Income/Loss:
$-84.95M
P/E Ratio:
-0.8199
EPS:
-1.9332
Net Cash Flow:
$-88.92M
1W Performance:
-3.37%
1M Performance:
-12.98%
6M Performance:
-34.65%
1Y Performance:
-17.97%
1-Day Range:
$1.55
$1.62
1-Week Range:
$1.55
$1.72
52-Week Range:
$1.30
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.58 | 109.01M | 65,300 | -84.95M | -88.92M | -1.9332 |
VRTX
Vertex Pharmaceuticals Inc
|
455.69 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
745.11 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
689.96 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
144.98 | 29.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
INO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 - The Malaysian Reserve
2026-03-22 | INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Class Action LawsuitContact Bronstein, Gewirtz and Grossman, LLC Today! | NDAQ:INO | Press Release - Stockhouse
If You Invested $1,000 in Inovio Pharmaceu (INO) - Stock Titan
INO FINAL DEADLINE: ROSEN, GLOBAL INVESTOR RIGHTS LAWYERS, Encourages Inovio Pharmaceuticals ... - Caledonian Record
INO FINAL DEADLINE: ROSEN, GLOBAL INVESTOR RIGHTS LAWYERS, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INO - GlobeNewswire Inc.
Short Squeeze: Is Inovio Pharmaceuticals Inc a turnaround story2026 Key Lessons & Real-Time Volume Spike Alerts - baoquankhu1.vn
Robbins LLP Reminds Inovio Pharmaceuticals, Inc. Stockholders of the Pending Class Action Against IN - PharmiWeb.com
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Aug Breakouts: Is Inovio Pharmaceuticals Inc in a consolidation phase2026 AllTime Highs & AI Powered Market Entry Strategies - baoquankhu1.vn
Robbins LLP Reminds Inovio Pharmaceuticals, Inc. Stockholders of the Pending Class Action Against INO and Urges Harmed Stockholders to Seek More Information - The AI Journal
INOVIO Reports 2025 Results as FDA Reviews Lead Drug Candidate - MyChesCo
INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. ... - Bluefield Daily Telegraph
Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Inovio - GlobeNewswire
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain OfficersINO - PR Newswire
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2025 Earnings Call Transcript - Insider Monkey
Inovio stock up on earnings, pipeline progress - MSN
INO Deadline: INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Barchart
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INO DEADLINE: ROSEN, A TOP-RANKED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors ... - Bluefield Daily Telegraph
INO CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) ... - Bluefield Daily Telegraph
Inovio (INO) Q4 2025 Earnings Call Transcript - AOL.com
LEVI & KORSINSKY, LLP: APRIL 7, 2026 — DEADLINE TO SEEK LEAD PLAINTIFF ROLE IN INOVIO PHARMACEUTICALS SECURITIES CLASS ACTION - Morningstar
Equities Analysts Set Expectations for INO Q1 Earnings - MarketBeat
INOVIO to Present DNA Medicine Data at Two Scientific Conferences - MyChesCo
INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds In - GuruFocus
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 - PR Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc.and Certain Officers – INO - ChartMill
Holzer & Holzer, LLC Reminds Investors of April 7, 2026 - GlobeNewswire
Inovio Pharmaceuticals Q4 2025 earnings preview - MSN
DEADLINE ALERT for TCPC, ORCL, PSFE, and INO: The Law - GlobeNewswire
INO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit -- The Gross Law Firm - PR Newswire
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Levi & Korsinsky, LLP: CEO and CFO Named as Control Person Defendants in Inovio Pharmaceuticals Securities Action - GlobeNewswire
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Inovio Investors Urged to Join Securities Fraud Lawsuit - National Today
Portnoy Law Firm Announces Class Action on Behalf of Inovio Pharmaceuticals, Inc. Investors - GlobeNewswire
INOVIO Pharmaceuticals spotlights INO-3107 potential in HPV-related cancer treatment at Eurogin - Traders Union
Inovio Pharmaceuticals: Balancing INO-3107 Regulatory Uncertainty and Early-Stage Pipeline Potential Justifies Hold Rating and $3 Target - TipRanks
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Layoff Tracker: Inovio Slims Down as Lead Asset Nears Market - BioSpace
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Inovio - GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure ... - Caledonian Record
Boxer Capital Management LLC Purchases New Shares in Inovio Pharmaceuticals, Inc. $INO - MarketBeat
Inovio Stock Up On Earnings, Pipeline Progress - Sahm
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded at Wall Street Zen - MarketBeat
INO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):